Uncategorized

The Uncoupling of Device and Drug: A Strategic Post-Mortem of Teva v. Amneal and the New Era of Orange Book Rigor

In the rapidly evolving landscape of pharmaceutical innovation, the lines between drug development and device integration are blurring—sometimes to the detriment of market stability and strategic clarity. Recent legal battles and regulatory shifts, exe…

The Uncoupling of Device and Drug: A Strategic Post-Mortem of Teva v. Amneal and the New Era of Orange Book Rigor Read Post »

Uncategorized

The Billion-Dollar Blind Spot: Why Traditional Drug Spend Forecasts Fail and How Patent Data Provides the Missing Link

The Billion-Dollar Blind Spot in Pharma Forecasting: Why Traditional Models Fail and How Patent Data Can Transform Your Strategy
Imagine investing millions into a new drug forecast only to find your predictions fall woefully short—costing your company …

The Billion-Dollar Blind Spot: Why Traditional Drug Spend Forecasts Fail and How Patent Data Provides the Missing Link Read Post »

Biotechblog
Scroll to Top